Skip to main content
Contact Us
Subscribe
E-Edition
67°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Deciphera Pharmaceuticals Inc
(NQ:
DCPH
)
14.67
+0.09 (+0.62%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Deciphera Pharmaceuticals Inc
< Previous
1
2
3
4
Next >
Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now
August 21, 2023
Biotech stocks may offer some of the most explosive opportunities on the market. Here are three with major catalysts nearing.
Via
InvestorPlace
3 Under-the-Radar Biotech Stocks to Buy in 2023
August 19, 2023
All three biotech companies focus on oncology therapies.
Via
The Motley Fool
Why Shares of Deciphera Pharmaceuticals Rose This Week
August 11, 2023
The company's shares rose after the company reported second-quarter earnings.
Via
The Motley Fool
Deciphera Pharmaceuticals Sees Renewed Competitive Edge After Theseus Pan-KIT Discontinuation: Analyst
August 10, 2023
Stifel upgraded Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) to Buy from Hold, with a price target of $20 from $14, after reevaluating the competitive landscape for the 2L GIST market.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
August 10, 2023
Via
Benzinga
Earnings Preview: Deciphera Pharmaceuticals
August 08, 2023
Via
Benzinga
Earnings Scheduled For February 6, 2024
February 06, 2024
Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion.
Via
Benzinga
Earnings Outlook For Deciphera Pharmaceuticals
February 05, 2024
Via
Benzinga
What 4 Analyst Ratings Have To Say About Deciphera Pharmaceuticals
November 20, 2023
Via
Benzinga
Deciphera Pharmaceuticals' Investigational Drug Shows Encouraging Response Rates In Rare Type Of Cancer
October 30, 2023
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) announced top-line results from the MOTION Phase 3 study of vimseltinib in patients with Tenosynovial Giant Cell Tumor (TGCT)
Via
Benzinga
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
October 30, 2023
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
The Latest Analyst Ratings for Deciphera Pharmaceuticals
May 04, 2023
Via
Benzinga
Recap: Deciphera Pharmaceuticals Q1 Earnings
May 03, 2023
Via
Benzinga
Preview: Deciphera Pharmaceuticals's Earnings
May 02, 2023
Via
Benzinga
Where Deciphera Pharmaceuticals Stands With Analysts
March 15, 2023
Via
Benzinga
Looking Into Deciphera Pharmaceuticals's Return On Capital Employed
February 08, 2023
Via
Benzinga
Global Payments To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Thursday
August 10, 2023
Keybanc cut the price target for i3 Verticals, Inc. (NASDAQ: IIIV) from $28 to $26. Keybanc analyst Josh Beck maintained an Overweight rating. i3 Verticals shares fell 2.9% to close at $22.76 on...
Via
Benzinga
Why Deciphera Pharmaceuticals Stock Jumped This Week
March 16, 2023
The company's lead therapy received an FDA Breakthrough Therapy designation.
Via
The Motley Fool
Stifel Is Bullish On This 'Competitive Late-Comer' In Gastric Cancer Space
March 16, 2023
Via
Benzinga
Top 5 Health Care Stocks That May Rocket Higher In Q1 2023
February 27, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Earnings Outlook For Deciphera Pharmaceuticals
February 06, 2023
Via
Benzinga
The Latest Analyst Ratings for Deciphera Pharmaceuticals
January 25, 2023
Via
Benzinga
$30M Bet On Deciphera Pharmaceuticals? Check Out These 4 Stocks Insiders Are Buying
January 25, 2023
Although US stocks closed mixed on Tuesday, there were a few notable insider trades.
Via
Benzinga
Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
January 19, 2023
Gainers Genius Group Limited (NYSE: GNS) jumped 87% to $1.00. Genius Group authorized issue of special dividend and appointed Timothy Murphy to lead Illegal Trading Task Force.
Via
Benzinga
Dow Falls 200 Points; Jobless Claims Drop To 4-Month Low
January 19, 2023
U.S. stocks traded lower this morning, with the Dow Jones dropping around 200 points on Thursday.
Via
Benzinga
Why Deciphera Pharmaceuticals Stock Is Nosediving
January 19, 2023
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) shares are trading lower by 10.48% to $18.45 Thursday morning after the company announced a $125 million proposed public offering of common stock.
Via
Benzinga
Why Starbox Group Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
January 19, 2023
Gainers Tricida, Inc. (NASDAQ: TCDA) rose 37.7% to $0.1898 in pre-market trading after gaining 4% on Wednesday.
Via
Benzinga
Alcoa, H.B. Fuller And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
January 19, 2023
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 04, 2023
Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
January 06, 2023
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.